Ads
-
Related paper
- Atherogenic Dyslipidemia: An Important Risk Factor for Cardiovascular Disease in Metabolic Syndrome and Type 2 Diabetes Mellitus Patients
- Hepatic fibrosis as an additional risk factor for the development of cardiovascular disorders in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Postprandial Dyslipidemia: Emerging lipid profile for cardiovascular disease risk in Type 2 Diabetes Mellitus subjects: A case control study. J Pharm Biomed Sci. 2015; 05(06):491-498
- A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus
- LIPID HOMEOSTASIS PECULARITIES IN ISCHEMIC HEART DISEASE PATIENTS WITH HEART FAILURE SYMPTOMS, DIABETES MELLITUS 2 TYPE AND METABOLIC SYNDROME DEPENDING ON MEDICATION PECULIARITIES
- AN EXPERIENCE OF USING SIMVASTATINUM IN THE METABOLIC SYNDROME OF PATIENTS WITH CHRONIC CHOLECYSTITIS AND DIABETES MELLITUS TYPE II
- GLYCOSYLATED HEMOGLOBIN AS A RISK ASSESSMENT OF THE CARDIOVASCULAR LESIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- Administration of Tadalafil to Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Prospective Randomized Clinical Trial
- Epidemiological and Metabolic Aspects and Risk Factors of Chronic Kidney Disease in Comorbid Pathology of Type 2 Diabetes Mellitus and Primary Hypothyroidism
- The Association between Left Ventricular Myocardial Strains and Risk Factors of Cardiovascular Disease in a Population with Type 2 Diabetes Mellitus: A Primary Controlled Cross-Sectional Study